PL2194987T3 - Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych - Google Patents

Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych

Info

Publication number: PL2194987T3
Authority: PL; Poland
Prior art keywords: inhibitors; stem cell; cancer stem; stat3 pathway; novel stat3
Prior art date: 2007-09-10

Application number

PL08830471T

Other languages

English (en)

Inventor

Zhiwei Jiang

Chiang Jia Li

Wei Li

David Leggett

Original Assignee

Boston Biomedical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-10

Filing date

2008-09-10

Publication date

2017-01-31

2008-09-10 Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc

2017-01-31 Publication of PL2194987T3 publication Critical patent/PL2194987T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Transplantation (AREA)
Biophysics (AREA)

PL08830471T 2007-09-10 2008-09-10 Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych PL2194987T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97114407P	2007-09-10	2007-09-10
US1337207P	2007-12-13	2007-12-13

Publications (1)

Publication Number	Publication Date
PL2194987T3 true PL2194987T3 (pl)	2017-01-31

Family

ID=40452461

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL08830471T PL2194987T3 (pl)	2007-09-10	2008-09-10	Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych
PL08830633T PL2200431T3 (pl)	2007-09-10	2008-09-10	Nowe kompozycje i metody służące leczeniu raka
PL16156278T PL3067054T3 (pl)	2007-09-10	2008-09-10	Nowe kompozycje i sposoby leczenia nowotworów
PL08830619.6T PL2190429T3 (pl)	2007-09-10	2008-09-10	Nowa grupa inhibitorów szlaku białka stat3 oraz inhibitorów szlaku nowotworowych komórek macierzystych

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
PL08830633T PL2200431T3 (pl)	2007-09-10	2008-09-10	Nowe kompozycje i metody służące leczeniu raka
PL16156278T PL3067054T3 (pl)	2007-09-10	2008-09-10	Nowe kompozycje i sposoby leczenia nowotworów
PL08830619.6T PL2190429T3 (pl)	2007-09-10	2008-09-10	Nowa grupa inhibitorów szlaku białka stat3 oraz inhibitorów szlaku nowotworowych komórek macierzystych

Country Status (14)

Country	Link
US (12)	US9732055B2 (pl)
EP (6)	EP3050566B1 (pl)
JP (16)	JP5688840B2 (pl)
CN (6)	CN101854802B (pl)
CA (4)	CA2736563C (pl)
CY (3)	CY1117604T1 (pl)
DK (4)	DK2190429T3 (pl)
ES (3)	ES2583010T3 (pl)
HR (3)	HRP20160430T1 (pl)
HU (3)	HUE029111T2 (pl)
PL (4)	PL2194987T3 (pl)
PT (2)	PT2200431T (pl)
SI (3)	SI2190429T1 (pl)
WO (3)	WO2009036059A2 (pl)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2405566C2 (ru)	2005-02-03	2010-12-10	Дзе Дженерал Хоспитал Корпорейшн	Способ лечения рака, устойчивого к гефитинибу
CA2626326C (en)	2005-11-04	2021-02-16	Wyeth	Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP5688840B2 (ja) *	2007-09-10	2015-03-25	ボストンバイオメディカル，インコーポレイテッド	新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en)	2007-11-09	2013-12-12	Fox Chase Cancer Center	Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) *	2007-11-09	2009-05-14	Fox Chase Cancer Center	EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
UY31800A (es) *	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2656844B1 (en)	2008-06-17	2014-12-03	Wyeth LLC	Antineoplastic combinations containing HKI-272 and vinorelbine
JP5675606B2 (ja)	2008-07-08	2015-02-25	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
EP2326329B1 (en)	2008-08-04	2017-01-11	Wyeth LLC	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8685941B2 (en)	2008-12-01	2014-04-01	University Of Central Florida Research Foundation, Inc.	Drug composition cytotoxic for pancreatic cancer cells
FI3000467T3 (fi)	2009-04-06	2023-03-28	Wyeth Llc	Rintasyöpähoitokuuri, jossa käytetään neratinibia
CN101897979B (zh) *	2009-05-27	2012-08-22	上海市计划生育科学研究所	治疗前列腺疾病的靶向药物
US20130129675A1 (en) *	2009-12-04	2013-05-23	Board Of Regents, The University Of Texas System	Interferon therapies in combination with blockade of stat3 activation
WO2011081205A1 (ja) *	2009-12-28	2011-07-07	一般社団法人ファルマＩｐ	１，３，４－オキサジアゾール－２－カルボキサミド化合物
US20110275577A1 (en) *	2010-01-08	2011-11-10	Moleculin, Llc	Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
AU2011223883B2 (en)	2010-03-01	2015-10-08	Cavion, Inc.	Cancer diagnosis and imaging
WO2011116398A1 (en) *	2010-03-19	2011-09-22	Boston Biomedical, Inc.	Novel compounds and compositions for targeting cancer stem cells
AU2015218436B9 (en) *	2010-03-19	2017-03-09	Boston Biomedical, Inc.	Novel Methods For Targeting Cancer Stem Cells
CA2793527A1 (en)	2010-03-19	2011-09-22	Boston Biomedical, Inc.	Use of naphthofuran derivatives in the treatment of cancer
CA2993363A1 (en) *	2010-03-19	2011-09-22	Boston Biomedical, Inc.	Naphthofuran compounds and compositions for targeting cancer stem cells
WO2011130677A1 (en) *	2010-04-16	2011-10-20	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Inhibitors of cancer stem cells
US20110301194A1 (en) *	2010-06-02	2011-12-08	Arqule, Inc.	Method for Determining Treatment Efficacy
CN103153975B (zh) *	2010-08-24	2016-01-20	杭州益尔生物科技有限公司	用于疾病治疗的新型萘醌
WO2012036214A1 (ja) *	2010-09-16	2012-03-22	国立大学法人大阪大学	自己免疫疾患、炎症性疾患、アレルギー性疾患、臓器移植に伴う症状の治療薬および予防薬
US20130252956A1 (en) *	2010-11-22	2013-09-26	Howard Kallender	Methods of treating cancer
US20130230581A1 (en) *	2010-11-30	2013-09-05	Qingping Feng	Egfr antagonist for the treatment of heart disease
WO2012078982A2 (en) *	2010-12-09	2012-06-14	The Ohio State University	Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
CN103402993A (zh) *	2011-03-04	2013-11-20	舟山海中洲新生药业有限公司	用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
KR20120130658A (ko) *	2011-05-23	2012-12-03	주식회사 파멥신	펩타이드가 융합된 이중표적항체 및 그 용도
MX2013014310A (es) *	2011-06-06	2014-01-23	Akebia Therapeutics Inc	Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
CN103957923B (zh) *	2011-09-12	2018-05-25	卡维昂公司	用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂
CA2855368A1 (en) *	2011-11-11	2013-05-16	Millennium Pharmaceuticals, Inc.	Biomarkers of response to proteasome inhibitors
CN104080449A (zh) *	2012-02-17	2014-10-01	舟山海中洲新生药业有限公司	4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013166618A1 (en) *	2012-05-08	2013-11-14	Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.	PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
KR102427777B1 (ko)	2012-06-26	2022-08-01	델 마 파마슈티컬스	디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CN106421795A (zh) *	2012-10-08	2017-02-22	贾力	预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de)	2013-02-25	2014-09-11	Thomas Rühl	Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
EP2983674A4 (en)	2013-04-08	2017-05-10	Dennis M. Brown	Therapeutic benefit of suboptimally administered chemical compounds
MX2015014181A (es) *	2013-04-09	2016-05-24	Boston Biomedical Inc	2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
KR102190322B1 (ko) *	2013-04-29	2020-12-11	오제데2 파르마	암줄기세포 암에 대한 새로운 치료적 진단적 전략으로서 o-아세틸화된-gd2 갱글리오사이드 타겟화
US10745489B2 (en)	2013-04-29	2020-08-18	Ogd2 Pharma	Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
UA121104C2 (uk)	2013-10-04	2020-04-10	Інфініті Фармасьютикалз, Інк.	Гетероциклічні сполуки і їх застосування
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9795595B2 (en) *	2014-01-27	2017-10-24	Boston Biomedical, Inc.	Methods for treating cancer
JP6695275B2 (ja) *	2014-02-07	2020-05-20	ボストンバイオメディカル，インコーポレイテッド	３−置換カルボニル−ナフト［２，３−ｂ］フラン誘導体又はその薬学的に許容される塩
WO2015120436A2 (en)	2014-02-10	2015-08-13	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Stat3 phosphorylation during graft-versus-host disease
CA2943075C (en)	2014-03-19	2023-02-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JP6894236B2 (ja) *	2014-03-26	2021-06-30	デノボバイオファーマエルエルシー	免疫刺激活性を有するレトロウイルスベクター
WO2015164870A1 (en)	2014-04-25	2015-10-29	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Gamma-aa-peptide stat3/dna inhibitors and methods of use
WO2015171985A1 (en) *	2014-05-09	2015-11-12	The Brigham And Women's Hospital, Inc.	Treatment of igg-immune complex-mediated organ damage
WO2015190489A1 (ja)	2014-06-09	2015-12-17	京都薬品工業株式会社	新規抗癌剤
AU2015289922A1 (en) *	2014-07-15	2017-02-16	The Johns Hopkins University	Suppression of myeloid derived suppressor cells and immune checkpoint blockade
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20160066490A (ko) *	2014-12-02	2016-06-10	주식회사 씨앤드씨신약연구소	헤테로사이클 유도체 및 그의 용도
CA2973484A1 (en)	2015-01-08	2016-07-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Furoquinolinediones as inhibitors of tdp2
JP6630364B2 (ja)	2015-03-27	2020-01-15	ボストンバイオメディカル，インコーポレイテッド	水溶性プロドラッグ
CN104725480A (zh) *	2015-04-06	2015-06-24	苏州普罗达生物科技有限公司	一种信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) *	2015-04-06	2015-06-10	苏州普罗达生物科技有限公司	信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) *	2015-04-06	2015-06-10	苏州普罗达生物科技有限公司	关于信号传导及转录激活因子抑制多肽及其应用
KR20180006919A (ko) *	2015-04-17	2018-01-19	보스톤 바이오메디칼, 인크.	암의 치료 방법
MX2017013360A (es) *	2015-04-17	2018-08-01	Boston Biomedical Inc	Métodos para tratar el cáncer.
AU2016249158A1 (en) *	2015-04-17	2017-11-02	Boston Biomedical, Inc.	Methods for treating cancer
JP2018514557A (ja) *	2015-04-27	2018-06-07	ボストンバイオメディカル，インコーポレイテッド	Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
EA201792509A1 (ru) *	2015-05-14	2018-05-31	НУКАНА ПиЭлСи	Лечение рака
CN108012529A (zh) *	2015-05-15	2018-05-08	诺华股份有限公司	治疗egfr突变的癌症的方法
AU2016271475A1 (en) *	2015-06-03	2017-12-21	Boston Biomedical, Inc.	Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
JP6810036B2 (ja)	2015-07-17	2021-01-06	大日本住友製薬株式会社	２−アセチル−４Ｈ，９Ｈ−ナフト［２，３−ｂ］フラン−４，９−ジオンの製造方法
WO2017013270A1 (en)	2015-07-23	2017-01-26	Universite De Strasbourg	Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) *	2015-07-31	2017-02-09	Boston Biomedical, Inc.	Method of targeting stat3 and other non-druggable proteins
EP3350183B1 (en)	2015-09-14	2025-04-02	Twelve Therapeutics, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN108135920A (zh)	2015-10-05	2018-06-08	努卡那有限公司	组合疗法
US20190017054A1 (en) *	2016-01-07	2019-01-17	Luni Emdad	Method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
CA3011800A1 (en)	2016-01-20	2017-08-03	Boston Biomedical, Inc.	Methods for treating cancer
CN109104862A (zh) *	2016-03-01	2018-12-28	中央研究院	4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途
US11946927B2 (en)	2016-03-14	2024-04-02	Musidora Biotechnology Llc	Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en)	2016-03-14	2019-05-21	Bruce Yacyshyn	Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017164379A1 (ja)	2016-03-25	2017-09-28	大日本住友製薬株式会社	２－アルキルカルボニルナフト［２，３－ｂ］フラン－４，９－ジオンの関連物質の製造方法、及びその関連物質
JP2017171640A (ja) *	2016-03-25	2017-09-28	学校法人兵庫医科大学	癌の治療システム
CN105837541A (zh) *	2016-04-23	2016-08-10	何淑琼	磷酸苯丙哌林的药物组合物及其在生物医药中的应用
CN105906595A (zh) *	2016-04-23	2016-08-31	陈斌	丙酸倍氯米松的药物组合物及其在生物医药中的应用
GB201609600D0 (en)	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Cancer treatments
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP2019519573A (ja)	2016-06-28	2019-07-11	ボストンバイオメディカル，インコーポレイテッド	がんを処置するための方法
CN106380456B (zh) *	2016-08-29	2019-03-26	中南大学	一种合成苯并呋喃萘醌衍生物的方法
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
US20190375723A1 (en)	2016-11-22	2019-12-12	Boston Biomedical, Inc.	New Naphtho[2,3-B]Furan Derivatives
US11299469B2 (en)	2016-11-29	2022-04-12	Sumitomo Dainippon Pharma Oncology, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
WO2018102506A1 (en) *	2016-11-30	2018-06-07	Tyme, Inc.	Tyrosine derivatives and compositions comprising them
US20190358212A1 (en) *	2017-01-22	2019-11-28	Jiangsu Hengrui Medicine Co., Ltd.	Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drug
US11963966B2 (en)	2017-03-31	2024-04-23	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating ovarian tumors
US10646464B2 (en)	2017-05-17	2020-05-12	Boston Biomedical, Inc.	Methods for treating cancer
WO2018225062A1 (en) *	2017-06-04	2018-12-13	Rappaport Family Institute For Research In The Medical Sciences	Method of predicting personalized response to cancer therapy and kit therefor
EP3654841B1 (en) *	2017-07-20	2024-02-07	Board Of Supervisors Of Louisiana State University	Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients
CA3074981A1 (en)	2017-09-22	2019-03-28	Sumitomo Dainippon Pharma Co., Ltd.	Chemically activated water-soluble prodrug
CN111479584A (zh) *	2017-11-16	2020-07-31	特尔诺沃有限公司	用于治疗癌症的irs/stat3双重调节剂和抗pd-1/pd-l1抗体的组合
EP3501511A1 (en) *	2017-12-22	2019-06-26	Fundación Centro Nacional De Investigaciones Oncológicas Carlos III	Means for preventing and treating brain metastasis
WO2019131940A1 (ja) *	2017-12-28	2019-07-04	株式会社カネカ	多能性幹細胞凝集抑制剤
CN107973788B (zh) *	2018-01-09	2021-07-09	沈阳药科大学	Bbi608衍生物及其制备与用途
AU2019239481B2 (en) *	2018-03-20	2022-11-24	Sumitomo Pharma Co., Ltd.	Dihydrochromene derivative
BR112020021329A2 (pt) *	2018-04-19	2021-04-27	Tvardi Therapeutics, Inc.	inibidores de stat3
WO2019232214A1 (en)	2018-05-31	2019-12-05	Boston Biomedical, Inc.	Methods of using napabucasin
AU2019341976A1 (en) *	2018-09-18	2021-04-15	General Incorporated Association Pharma Valley Project Supporting Organization	Cancer combination therapy using quinoline carboxamide derivative
MX2021004151A (es) *	2018-10-12	2021-09-08	1Globe Biomedical Co Ltd	Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.
CN109223758A (zh) *	2018-10-31	2019-01-18	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109846888A (zh) *	2018-10-31	2019-06-07	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109331004A (zh) *	2018-10-31	2019-02-15	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109966297A (zh) *	2018-10-31	2019-07-05	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109288846A (zh) *	2018-10-31	2019-02-01	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109172563A (zh) *	2018-10-31	2019-01-11	南京先进生物材料与过程装备研究院有限公司	一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109200044A (zh) *	2018-10-31	2019-01-15	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109288845A (zh) *	2018-10-31	2019-02-01	南京先进生物材料与过程装备研究院有限公司	一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109288847A (zh) *	2018-10-31	2019-02-01	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109200052A (zh) *	2018-10-31	2019-01-15	南京先进生物材料与过程装备研究院有限公司	一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109364252B (zh) *	2018-11-21	2021-09-28	南京大学	抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020207344A1 (zh) *	2019-04-09	2020-10-15	健艾仕生物医药有限公司	匹莫齐特和甲氨蝶呤的药物组合及其应用
US11564913B2 (en) *	2019-05-03	2023-01-31	Children's Hospital Medical Center	Compositions and methods for treating cancer
CN110218198B (zh) *	2019-05-22	2022-06-28	广州中医药大学(广州中医药研究院)	一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
WO2020251015A1 (ja) *	2019-06-14	2020-12-17	大日本住友製薬株式会社	２－アルキルカルボニル［２，３－ｂ］フラン－４，９－ジオンの製造方法、及びその製造中間体
JP7287929B2 (ja) *	2019-09-25	2023-06-06	住友ファーマ株式会社	ジヒドロクロメン誘導体を含有する医薬
CN114761006A (zh) *	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
TW202131923A (zh) *	2019-11-20	2021-09-01	耶魯大學	用於治療局部缺血-再灌注損傷及/或肺損傷的化合物、組成物及方法
KR20220124170A (ko) *	2019-12-05	2022-09-13	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	간 섬유증 및 섬유증 관련 기타 질환에 대한 엑소좀 기반 치료요법
CN115135326B (zh) *	2020-03-16	2024-09-13	正大天晴药业集团股份有限公司	作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
JP2023525767A (ja) *	2020-05-11	2023-06-19	パーデュー・リサーチ・ファウンデーション	連続フロー条件下でのロムスチンのスケールアップ合成
CN114286684B (zh) *	2020-07-27	2024-01-05	华中科技大学	与stat3相关的疾病的预防和/或治疗
WO2022216930A1 (en) *	2021-04-08	2022-10-13	Virginia Commonwealth University	Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) *	2022-03-03	2024-03-01	陕西中医药大学	一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2472133A (en) *	1947-03-20	1949-06-07	Du Pont	Thiophanthraquinone derivatives
SU1049490A1 (ru)	1982-05-18	1983-10-23	Ордена Трудового Красного Знамени Институт Химии Ан Мсср	(3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja)	1984-06-20	1986-01-11	Mitsubishi Electric Corp	無機絶縁体の製法
JPS63196576A (ja) *	1987-02-10	1988-08-15	Tetsuo Ikegawa	フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de)	1987-09-29	1990-12-05	Siemens Aktiengesellschaft	Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja)	1987-11-06	1989-05-12	Eisai Co Ltd	トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr)	1989-05-31	1990-12-12	BODET, Jean Augustin	Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) *	1989-12-28	1992-05-13	Dainippon Ink & Chem Inc	フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
DE69131873T2 (de) *	1990-07-10	2000-06-15	Canon K.K., Tokio/Tokyo	Elektrophotographisches, lichtempfindliches Element
JP2942015B2 (ja) *	1990-07-10	1999-08-30	キヤノン株式会社	電子写真感光体およびそれを用いた電子写真装置
TW252136B (pl) *	1992-10-08	1995-07-21	Ciba Geigy
JP3598168B2 (ja)	1996-03-18	2004-12-08	独立行政法人科学技術振興機構	抗ウイルス剤
JPH1121284A (ja)	1997-06-30	1999-01-26	Kotobuki:Kk	フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) *	1997-08-11	1999-03-05	Canon Inc	電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) *	1998-06-05	2001-01-16	The University Of North Carolina At Chapel Hill	Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
AU2736400A (en) *	1999-01-27	2000-08-18	University Of South Florida	Inhibition of stat3 signal transduction for human cancer therapy
DE60042968D1 (de)	1999-04-01	2009-10-29	Hana Biosciences Inc	Zusammensetzungen und methoden zur behandlung lymphoma
US6482943B1 (en) *	1999-04-30	2002-11-19	Slil Biomedical Corporation	Quinones as disease therapies
JP3961827B2 (ja) *	1999-08-02	2007-08-22	エフ．ホフマン−ラロシュアーゲー	新規な選択的レチノイドアゴニスト
JP2001097860A (ja)	1999-09-29	2001-04-10	Japan Science & Technology Corp	抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) *	2000-03-13	2001-11-14	박호군	여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
WO2002078617A2 (en)	2001-03-28	2002-10-10	University Of South Florida	Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en)	2001-07-20	2001-09-12	Bradford Particle Design Plc	Particle information
US20040092428A1 (en)	2001-11-27	2004-05-13	Hongming Chen	Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
WO2003045979A2 (en)	2001-11-29	2003-06-05	Therakos, Inc.	Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
JP2005533748A (ja) *	2002-03-08	2005-11-10	シグナルファーマシューティカルズ，インコーポレイテッド	増殖性障害および癌を治療、予防、または管理するための併用療法
DE60307701T2 (de) *	2002-03-15	2007-10-11	Natimmune A/S	Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
WO2004024145A1 (en)	2002-09-10	2004-03-25	Dabur Research Foundation	Anti-cancer activity of carvedilol and its isomers
EP1551392A4 (en)	2002-09-17	2006-09-20	Arqule Inc	NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
TWI323662B (en)	2002-11-15	2010-04-21	Telik Inc	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TWI335913B (en)	2002-11-15	2011-01-11	Vertex Pharma	Diaminotriazoles useful as inhibitors of protein kinases
IS6633A (is) *	2002-11-22	2004-05-23	Omega Farma Ehf.	Samsetningar af fínasteríð töflum
KR20060031809A (ko) *	2003-06-09	2006-04-13	더 리젠츠 오브 더 유니버시티 오브 미시간	암 치료 및 진단용 조성물 및 방법
JP2007502777A (ja)	2003-08-13	2007-02-15	ユニバーシティーオブサウスフロリダ	腫瘍の処置のための白金錯体
US20050049207A1 (en) *	2003-09-03	2005-03-03	Kaufmann Doug A.	Method of treating and preventing cancer
WO2005033048A2 (en) *	2003-09-29	2005-04-14	The Johns Hopkins University	Wnt pathway antagonists
PL1706133T3 (pl)	2003-12-02	2011-04-29	Cleveland Clinic Found	Sposoby ochrony przed promieniowaniem z użyciem flageliny
AU2004298511B2 (en) *	2003-12-11	2011-08-11	Board Of Regents, The University Of Texas System	Compounds for treatment of cell proliferative diseases
DE10359828A1 (de) *	2003-12-12	2005-07-28	Zoser B. Dr.Rer.Nat. Salama	CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
WO2005110477A2 (en) *	2004-04-09	2005-11-24	University Of South Florida	Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) *	2004-04-21	2004-08-12	Japan Science & Technology Agency	抗菌剤
MX2007000265A (es) *	2004-07-02	2007-07-20	Icos Corp	Compuestos utiles para inhibir chk1.
EP1781673B1 (en) *	2004-08-18	2009-10-21	AstraZeneca AB	Selected fused heterocyclics and uses thereof
CA2587276A1 (en) *	2004-11-08	2006-05-18	Baxter International Inc.	Nanoparticulate compositions of tubulin inhibitor compounds
BRPI0517887A (pt) *	2004-11-24	2008-10-21	Novartis Ag	combinações de inibidores de jaks
US7807662B2 (en) *	2004-12-23	2010-10-05	University Of South Florida	Platinum IV complex inhibitor
JP2008535785A (ja) *	2005-02-25	2008-09-04	ザリージェンツオブザユニバーシティオブミシガン	Ｓｔａｔ３の小分子阻害剤およびその使用
JP2006248978A (ja) *	2005-03-10	2006-09-21	Mebiopharm Co Ltd	新規なリポソーム製剤
JP2006290871A (ja)	2005-03-16	2006-10-26	Taheebo Japan Kk	抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) *	2005-04-18	2006-11-09	Regents Of The University Of Michigan	Compositions and methods for the treatment of cancer
JPWO2006126505A1 (ja)	2005-05-26	2008-12-25	国立大学法人東京大学	Ｓｔａｔ機能阻害剤およびその応用
WO2007013946A2 (en) *	2005-07-20	2007-02-01	University Of South Florida	Method of predicting responsiveness to chemotherapy and selecting treatments
WO2007042912A2 (en)	2005-10-13	2007-04-19	Orchid Research Laboratories Limited	Heterocyclic compounds as pstat3/il-6 inhibitors
UA96139C2 (uk) *	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) *	2005-11-23	2007-12-05	Merck & Co Inc	Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja)	2005-11-30	2007-06-14	Idemitsu Kosan Co Ltd	水素発生材料および水素発生方法
US20090209494A1 (en) *	2005-12-24	2009-08-20	Christine Janet Martin	21-deoxymacbecin analogues useful as antitumor agents
CA2635209A1 (en) *	2006-01-12	2007-08-02	Merck & Co., Inc.	Fluorinated arylamide derivatives
EP2001438A2 (en) *	2006-02-09	2008-12-17	Macusight, Inc.	Stable formulations, and methods of their preparation and use
US20070243192A1 (en) *	2006-02-21	2007-10-18	Regents Of The University Of Michigan	Growth hormone receptor antagonist cancer treatment
AU2007218966A1 (en) *	2006-02-24	2007-08-30	Merck Frosst Canada Ltd.	2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
WO2007115269A2 (en) *	2006-03-31	2007-10-11	The Board Of Regents Of The University Of Texas System	Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en)	2006-04-05	2007-10-11	Bristol-Myers Squibb Company	Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en)	2006-10-04	2008-08-07	Universtiy Of South Florida	Akt sensitization of cancer cells
WO2008077062A2 (en) *	2006-12-19	2008-06-26	Board Of Regents, The University Of Texas System	Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja)	2007-05-31	2008-04-23	タヒボジャパン株式会社	抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
JP5688840B2 (ja)	2007-09-10	2015-03-25	ボストンバイオメディカル，インコーポレイテッド	新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
WO2009060282A2 (en)	2007-11-06	2009-05-14	Orchid Research Laboratories Limited	Stilbene derivatives as pstat3/il-6 inhibitors
WO2011116398A1 (en)	2010-03-19	2011-09-22	Boston Biomedical, Inc.	Novel compounds and compositions for targeting cancer stem cells
CA2793527A1 (en)	2010-03-19	2011-09-22	Boston Biomedical, Inc.	Use of naphthofuran derivatives in the treatment of cancer
AU2015218436B9 (en)	2010-03-19	2017-03-09	Boston Biomedical, Inc.	Novel Methods For Targeting Cancer Stem Cells
CA2993363A1 (en)	2010-03-19	2011-09-22	Boston Biomedical, Inc.	Naphthofuran compounds and compositions for targeting cancer stem cells
CN103402993A (zh)	2011-03-04	2013-11-20	舟山海中洲新生药业有限公司	用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
US8977803B2 (en)	2011-11-21	2015-03-10	Western Digital Technologies, Inc.	Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en)	2012-05-08	2013-11-14	Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.	PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
MX2015014181A (es)	2013-04-09	2016-05-24	Boston Biomedical Inc	2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
KR20180006919A (ko)	2015-04-17	2018-01-19	보스톤 바이오메디칼, 인크.	암의 치료 방법
MX2017013360A (es)	2015-04-17	2018-08-01	Boston Biomedical Inc	Métodos para tratar el cáncer.
AU2016249158A1 (en)	2015-04-17	2017-11-02	Boston Biomedical, Inc.	Methods for treating cancer
JP2018514557A (ja)	2015-04-27	2018-06-07	ボストンバイオメディカル，インコーポレイテッド	Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
AU2016271475A1 (en)	2015-06-03	2017-12-21	Boston Biomedical, Inc.	Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
CA3011800A1 (en)	2016-01-20	2017-08-03	Boston Biomedical, Inc.	Methods for treating cancer
US10646464B2 (en)	2017-05-17	2020-05-12	Boston Biomedical, Inc.	Methods for treating cancer

2008
- 2008-09-10 JP JP2010524243A patent/JP5688840B2/ja not_active Expired - Fee Related
- 2008-09-10 PL PL08830471T patent/PL2194987T3/pl unknown
- 2008-09-10 CN CN200880115249.XA patent/CN101854802B/zh active Active
- 2008-09-10 HR HRP20160430TT patent/HRP20160430T1/hr unknown
- 2008-09-10 EP EP16156335.8A patent/EP3050566B1/en active Active
- 2008-09-10 WO PCT/US2008/075848 patent/WO2009036059A2/en active Application Filing
- 2008-09-10 SI SI200831606A patent/SI2190429T1/sl unknown
- 2008-09-10 HR HRP20160949TT patent/HRP20160949T1/hr unknown
- 2008-09-10 CA CA2736563A patent/CA2736563C/en not_active Expired - Fee Related
- 2008-09-10 DK DK08830619.6T patent/DK2190429T3/en active
- 2008-09-10 CN CN2008801152470A patent/CN101854937B/zh active Active
- 2008-09-10 EP EP08830471.2A patent/EP2194987B1/en active Active
- 2008-09-10 DK DK08830471.2T patent/DK2194987T3/en active
- 2008-09-10 CN CN201410583457.XA patent/CN104586832B/zh active Active
- 2008-09-10 EP EP16156278.0A patent/EP3067054B1/en active Active
- 2008-09-10 ES ES08830471.2T patent/ES2583010T3/es active Active
- 2008-09-10 ES ES08830619.6T patent/ES2569215T3/es active Active
- 2008-09-10 CA CA2736564A patent/CA2736564A1/en not_active Abandoned
- 2008-09-10 EP EP08830633.7A patent/EP2200431B1/en active Active
- 2008-09-10 DK DK16156335.8T patent/DK3050566T3/en active
- 2008-09-10 SI SI200831655A patent/SI2200431T1/sl unknown
- 2008-09-10 HR HRP20160625TT patent/HRP20160625T1/hr unknown
- 2008-09-10 US US12/677,516 patent/US9732055B2/en active Active
- 2008-09-10 PT PT88306337T patent/PT2200431T/pt unknown
- 2008-09-10 CN CN200880115250.2A patent/CN101854930B/zh active Active
- 2008-09-10 PL PL08830633T patent/PL2200431T3/pl unknown
- 2008-09-10 CA CA2911990A patent/CA2911990C/en not_active Expired - Fee Related
- 2008-09-10 DK DK08830633.7T patent/DK2200431T3/en active
- 2008-09-10 PL PL16156278T patent/PL3067054T3/pl unknown
- 2008-09-10 HU HUE08830633A patent/HUE029111T2/en unknown
- 2008-09-10 US US12/677,513 patent/US9745278B2/en active Active
- 2008-09-10 CA CA2736532A patent/CA2736532C/en not_active Expired - Fee Related
- 2008-09-10 CN CN201610134121.4A patent/CN105963289B/zh active Active
- 2008-09-10 JP JP2010524249A patent/JP5701603B2/ja not_active Expired - Fee Related
- 2008-09-10 WO PCT/US2008/075906 patent/WO2009036101A1/en active Application Filing
- 2008-09-10 CN CN201310052882.1A patent/CN103288787B/zh active Active
- 2008-09-10 WO PCT/US2008/075903 patent/WO2009036099A1/en active Application Filing
- 2008-09-10 PL PL08830619.6T patent/PL2190429T3/pl unknown
- 2008-09-10 US US12/677,511 patent/US8877803B2/en not_active Expired - Fee Related
- 2008-09-10 ES ES08830633.7T patent/ES2584904T3/es active Active
- 2008-09-10 JP JP2010524251A patent/JP5872160B2/ja not_active Expired - Fee Related
- 2008-09-10 EP EP16156290.5A patent/EP3058941B1/en active Active
- 2008-09-10 EP EP08830619.6A patent/EP2190429B1/en active Active
- 2008-09-10 PT PT88304712T patent/PT2194987T/pt unknown
- 2008-09-10 SI SI200831626A patent/SI2194987T1/sl unknown
- 2008-09-10 HU HUE08830471A patent/HUE027657T2/en unknown
- 2008-09-10 HU HUE08830619A patent/HUE027443T2/en unknown
2014
- 2014-09-02 JP JP2014177915A patent/JP5938072B2/ja not_active Expired - Fee Related
- 2014-09-02 JP JP2014177908A patent/JP5925849B2/ja not_active Expired - Fee Related
- 2014-09-29 US US14/499,299 patent/US9834532B2/en active Active
- 2014-11-17 JP JP2014232396A patent/JP6106149B2/ja not_active Expired - Fee Related
- 2014-11-17 JP JP2014232397A patent/JP2015034179A/ja not_active Withdrawn
2015
- 2015-11-26 JP JP2015230291A patent/JP6358659B2/ja not_active Expired - Fee Related
2016
- 2016-01-13 JP JP2016004076A patent/JP6347795B2/ja not_active Expired - Fee Related
- 2016-02-01 JP JP2016016973A patent/JP6346628B2/ja not_active Expired - Fee Related
- 2016-05-11 CY CY20161100393T patent/CY1117604T1/el unknown
- 2016-05-16 JP JP2016097607A patent/JP2016147906A/ja not_active Withdrawn
- 2016-07-19 CY CY20161100701T patent/CY1118476T1/el unknown
- 2016-07-26 CY CY20161100733T patent/CY1117833T1/el unknown
2017
- 2017-02-10 US US15/429,939 patent/US20170197932A1/en not_active Abandoned
- 2017-07-11 US US15/647,054 patent/US20180030021A1/en not_active Abandoned
- 2017-07-20 US US15/655,366 patent/US20180030022A1/en not_active Abandoned
- 2017-12-19 JP JP2017242778A patent/JP2018076349A/ja not_active Withdrawn
2018
- 2018-05-29 JP JP2018102234A patent/JP2018131464A/ja not_active Withdrawn
- 2018-10-16 US US16/161,413 patent/US10851075B2/en not_active Expired - Fee Related
- 2018-12-31 US US16/236,948 patent/US20200039948A1/en not_active Abandoned
2019
- 2019-01-14 US US16/246,829 patent/US10377731B2/en not_active Expired - Fee Related
- 2019-02-21 JP JP2019029436A patent/JP2019073560A/ja active Pending
2020
- 2020-05-14 JP JP2020085065A patent/JP2020117547A/ja active Pending
- 2020-05-15 US US16/875,479 patent/US20210024482A1/en not_active Abandoned
- 2020-05-26 JP JP2020091326A patent/JP2020143135A/ja active Pending
- 2020-10-09 US US17/066,885 patent/US20210115006A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2194987T3 (en)	2016-08-15
JP2010539098A (ja)	2010-12-16
EP2194987A4 (en)	2011-11-30
PL2200431T3 (pl)	2017-01-31
JP2018131464A (ja)	2018-08-23
JP5701603B2 (ja)	2015-04-15
EP3050566B1 (en)	2018-11-28
JP6346628B2 (ja)	2018-06-20
ES2583010T3 (es)	2016-09-16
HRP20160949T1 (hr)	2016-10-07
EP2190429A4 (en)	2011-12-14
CN103288787A (zh)	2013-09-11
JP6106149B2 (ja)	2017-03-29
CN104586832B (zh)	2018-02-16
JP2016094465A (ja)	2016-05-26
CN101854930A (zh)	2010-10-06
DK2190429T3 (en)	2016-05-30
EP3067054A1 (en)	2016-09-14
JP6347795B2 (ja)	2018-06-27
US9732055B2 (en)	2017-08-15
JP2010539095A (ja)	2010-12-16
PT2200431T (pt)	2016-08-03
US20210024482A1 (en)	2021-01-28
CA2736563A1 (en)	2009-03-19
US20180030022A1 (en)	2018-02-01
CA2736563C (en)	2016-01-26
JP2014221843A (ja)	2014-11-27
HRP20160430T1 (hr)	2016-05-20
US8877803B2 (en)	2014-11-04
US20200039948A1 (en)	2020-02-06
JP5938072B2 (ja)	2016-06-22
US9834532B2 (en)	2017-12-05
US20180030021A1 (en)	2018-02-01
CN101854930B (zh)	2016-05-04
EP2200431B1 (en)	2016-07-20
ES2584904T3 (es)	2016-09-30
US20110112180A1 (en)	2011-05-12
US20190263768A1 (en)	2019-08-29
EP3050566A2 (en)	2016-08-03
WO2009036059A2 (en)	2009-03-19
EP3067054B1 (en)	2020-12-30
CY1117833T1 (el)	2017-05-17
US10851075B2 (en)	2020-12-01
EP2194987A2 (en)	2010-06-16
US20150018410A1 (en)	2015-01-15
CN103288787B (zh)	2016-08-03
WO2009036101A1 (en)	2009-03-19
US20210115006A1 (en)	2021-04-22
CA2736532A1 (en)	2009-03-19
CN104586832A (zh)	2015-05-06
HRP20160625T1 (hr)	2016-08-12
JP5688840B2 (ja)	2015-03-25
CA2911990A1 (en)	2009-03-19
HK1148942A1 (zh)	2011-09-23
US20100310503A1 (en)	2010-12-09
WO2009036059A3 (en)	2009-07-02
WO2009036099A1 (en)	2009-03-19
CY1117604T1 (el)	2017-04-26
EP2200431A1 (en)	2010-06-30
HK1148906A1 (en)	2011-09-23
JP5872160B2 (ja)	2016-03-01
JP2016065101A (ja)	2016-04-28
CN101854802A (zh)	2010-10-06
JP2015038151A (ja)	2015-02-26
JP2016147906A (ja)	2016-08-18
JP6358659B2 (ja)	2018-07-18
PT2194987T (pt)	2016-08-05
US9745278B2 (en)	2017-08-29
SI2190429T1 (sl)	2016-10-28
CA2736532C (en)	2018-03-20
SI2200431T1 (sl)	2016-10-28
CN101854937A (zh)	2010-10-06
HK1148943A1 (en)	2011-09-23
JP2010539097A (ja)	2010-12-16
EP2190429B1 (en)	2016-04-20
JP5925849B2 (ja)	2016-05-25
ES2569215T3 (es)	2016-05-09
CN101854937B (zh)	2013-03-27
CN101854802B (zh)	2014-12-03
HUE027657T2 (en)	2016-11-28
US10377731B2 (en)	2019-08-13
JP2020143135A (ja)	2020-09-10
JP2014231522A (ja)	2014-12-11
DK2200431T3 (en)	2016-08-15
JP2018076349A (ja)	2018-05-17
SI2194987T1 (sl)	2016-10-28
CY1118476T1 (el)	2017-07-12
US20170197932A1 (en)	2017-07-13
DK3050566T3 (en)	2019-03-11
JP2019073560A (ja)	2019-05-16
HUE029111T2 (en)	2017-02-28
EP3058941A1 (en)	2016-08-24
CA2911990C (en)	2018-03-20
US20120252763A1 (en)	2012-10-04
CA2736564A1 (en)	2009-03-19
JP2015034179A (ja)	2015-02-19
HUE027443T2 (en)	2016-10-28
US20190135773A1 (en)	2019-05-09
PL2190429T3 (pl)	2016-09-30
JP2020117547A (ja)	2020-08-06
EP3050566A3 (en)	2016-11-30
CN105963289A (zh)	2016-09-28
EP2194987B1 (en)	2016-05-18
CN105963289B (zh)	2021-02-26
PL3067054T3 (pl)	2021-10-04
EP3058941B1 (en)	2019-05-22
JP2016034976A (ja)	2016-03-17
EP2200431A4 (en)	2011-12-21
EP2190429A1 (en)	2010-06-02

Publication	Publication Date	Title
EP2194987A4 (en)	2011-11-30	NEW STAT3 INHIBITORS AND NEW INHIBITORS OF CANCER STEM CELLS
HUS1700018I1 (hu)	2017-05-29	Proteoszóma inhibitorok
IL199836A0 (en)	2010-04-15	Human cancer stem cells
SI2299999T1 (sl)	2017-12-29	Stat3 inhibitorji
EP2200977A4 (en)	2011-12-28	F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
EP2184349A4 (en)	2011-10-26	ISOLATED CELL MASS
EP2214669A4 (en)	2011-11-09	cytokine inhibitors
IL201613A (en)	2015-02-26	Cell counting method and kit
EP2069477A4 (en)	2010-12-08	CHEMOREPULSION OF CELLS
SI2144639T1 (sl)	2013-03-29	Nova linija izvorne celice in uporaba le-te
IL211994A0 (en)	2011-06-30	Prostate stem cells and uses thereof
HK1229259A1 (en)	2017-11-17	A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2185685A4 (en)	2011-08-03	NEW PROCESSES AND NEW CELL LINES
GB0714941D0 (en)	2007-09-12	Inhibitors
PT2193793E (pt)	2012-09-28	Inibidor da morte de células nervosas
GB0724569D0 (en)	2008-01-30	Cancer stem cell markers
GB0605548D0 (en)	2006-04-26	Cell inhibitor
GB0708255D0 (en)	2007-06-06	Cysteine prtease inhibitors
GB0703543D0 (en)	2007-04-04	Cold cell
GB0707498D0 (en)	2007-05-23	Novel inhibitors
GB0704589D0 (en)	2007-04-18	Novel inhibitors
GB0707493D0 (en)	2007-05-23	Novel inhibitors
GB0707495D0 (en)	2007-05-23	Novel inhibitors
GB0707497D0 (en)	2007-05-23	Novel inhibitors
GB0707488D0 (en)	2007-05-23	Novel inhibitors